



## Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September

REDWOOD CITY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences in September, both being held in New York.

- A company presentation is scheduled at Baird's 2016 Global Healthcare Conference on Wednesday, September 7<sup>th</sup> at 9:40 a.m. ET
- Management participation in a fireside chat is scheduled at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13<sup>th</sup> at 10:00 a.m. ET

The audio portion of the presentation and fireside chat will be available on the investors page of the Coherus BioSciences website at <http://investors.coherus.com>.

### About Coherus BioSciences, Inc.

Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit [www.coherus.com](http://www.coherus.com).

### CONTACT: □

Patrick O'Brien  
Senior Vice President, Investor Relations  
Coherus BioSciences, Inc.  
[pobrien@coherus.com](mailto:pobrien@coherus.com)  
+1 (650) 649-3527



Coherus BioSciences, Inc.